Calquence and Eliglustat Tartrate

• Generic Name: acalabrutinib
• Dosage Forms: capsule, gelatin coated
• Other Brand Names: Calquence

Calquence (acalabrutinib) blocks the action of certain enzymes in the body, which can interfere with the growth and spread of cancer cells.

Calquence is used to treat mantle cell lymphoma (a type of non-Hodgkin lymphoma) in adults. This medicine is given after other treatments have failed.

Calquence was approved by the US Food and Drug Administration (FDA) on an "accelerated" basis. In clinical studies, patients responded to this medicine. However, further studies are needed.

Calquence is also used to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adults.

• Generic Name: eliglustat
• Dosage Forms: n.a.
• Other Brand Names: Cerdelga

Long-term treatment of nonneuronopathic (type 1) Gaucher disease in patients who are extensive, intermediate, or poor metabolizers of CYP2D6.

Patient selection and dosing based on CYP2D6 metabolizer status; determine patient's CYP2D6 genotype with an FDA-cleared test prior to initiating therapy.

Ultrarapid CYP2D6 metabolizers may not achieve adequate plasma concentrations to achieve a therapeutic effect. A specific dosage cannot be recommended for patients whose CYP2D6 genotype cannot be determined (indeterminate metabolizers).

Designated an orphan drug by FDA for treatment of type 1 Gaucher disease.